OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging
December 17, 2025
December 17, 2025
PORTLAND, Oregon, Dec. 17 -- Oregon Health and Science University issued the following news:
* * *
OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging
*
The Food and Drug Administration has approved ferumoxytol, known clinically as FERABRIGHT(tm), as a contrast agent physicians can use to detect and monitor tumor progression in patients with brain cancer.
Edward Neuwelt, M.D. (OHSU)
. . .
* * *
OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging
*
The Food and Drug Administration has approved ferumoxytol, known clinically as FERABRIGHT(tm), as a contrast agent physicians can use to detect and monitor tumor progression in patients with brain cancer.
Edward Neuwelt, M.D. (OHSU)
. . .